Skip to main content
. 2020 Apr 17;12(4):997. doi: 10.3390/cancers12040997

Figure 3.

Figure 3

High levels of ERBB4 are found in Group 4 medulloblastomas and are associated with poor clinical outcome. (AD) Boxplot of the log2 of ERBB4 expression in the indicated medulloblastoma subgroups in (A) Northcott et al. (2012) cohort (n = 1087), (B) Robinson et al. (2012) cohort (n = 76), (C) Remke et al. (2011) cohort (n = 64), and (D) Cavalli et al. (2017) cohort (n = 612). (E) ERBB4 mRNA expression in the indicated medulloblastoma cell lines (n ≥ 3). (F,G) Kaplan–Meier curves for the Cavalli et al. (2017) cohort’s Group 4 patients’ and all patients’ overall survival rates based on ERBB4 expression obtained from hgserver1.